Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Day One Biopharmaceuticals Inc (NQ: DAWN ) 14.80 -0.18 (-1.20%) Streaming Delayed Price Updated: 2:46 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 211,636 Open 15.09 Bid (Size) 14.79 (7) Ask (Size) 14.81 (3) Prev. Close 14.98 Today's Range 14.66 - 15.15 52wk Range 9.670 - 18.07 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal June 22, 2024 FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... Via Talk Markets Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers June 18, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Performance YTD +1.93% +1.93% 1 Month +8.19% +8.19% 3 Month -3.77% -3.77% 6 Month +5.71% +5.71% 1 Year +25.32% +25.32% More News Read More Day One Announces Sale of Priority Review Voucher for $108 Million May 30, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024 May 06, 2024 Via InvestorPlace Analyst Ratings for Day One Biopharmaceutical November 07, 2023 Via Benzinga The Latest Analyst Ratings for Day One Biopharmaceutical September 12, 2023 Via Benzinga Where Day One Biopharmaceutical Stands With Analysts August 08, 2023 Via Benzinga Day One Reports First Quarter 2024 Financial Results and Corporate Progress May 06, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor April 23, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress February 26, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Day One Announces Two New Appointments to Board of Directors January 17, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 19, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine November 17, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference November 14, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Day One Reports Third Quarter 2023 Financial Results and Corporate Progress November 06, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Dow Up Over 340 Points As Stocks Snap Back October 30, 2023 Via Talk Markets Topics Stocks Exposures US Equities Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday October 30, 2023 Via Benzinga Topics Stocks Exposures US Equities Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) October 30, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's After-Market Session October 26, 2023 Via Benzinga $15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying October 23, 2023 Via Benzinga Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) September 11, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience August 16, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Day One Reports Second Quarter 2023 Financial Results and Corporate Progress August 07, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire $3.6 Bet On Asana? Check Out These 4 Stocks Insiders Are Buying June 13, 2023 Via Benzinga Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares June 12, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
